Phase 1 studies to define the safety, tolerability, and pharmacokinetic and pharmacodynamic profiles of the nonsteroidal mineralocorticoid receptor antagonist …

T Nakamura, A Kawaguchi - Clinical Pharmacology in Drug …, 2021 - Wiley Online Library
Apararenone is a long‐acting, nonsteroidal mineralocorticoid receptor antagonist (MRA).
The safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of …
被引用次数：20 相关文章
[HTML] nih.gov

[HTML][HTML] Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor …

T Nakamura, A Kawaguchi - Clinical Pharmacology in Drug …, 2021 - ncbi.nlm.nih.gov
Apararenone is a long‐acting, nonsteroidal mineralocorticoid receptor antagonist (MRA).
The safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of …

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist …

T Nakamura, A Kawaguchi - Clinical pharmacology in …, 2021 - pubmed.ncbi.nlm.nih.gov
Apararenone is a long-acting, nonsteroidal mineralocorticoid receptor antagonist (MRA).
The safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of …

Phase 1 Studies to Define the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of the Nonsteroidal Mineralocorticoid Receptor Antagonist …

T Nakamura, A Kawaguchi - Clinical Pharmacology in Drug …, 2020 - europepmc.org
Apararenone is a long‐acting, nonsteroidal mineralocorticoid receptor antagonist (MRA).
The safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles of …